NCT06292858 2024-03-05
Safety/Tolerability, PK and Efficacy of IMB071703 Injection in Patients With Advanced Solid Tumors
Beijng Immunoah Pharma Tech Co., Ltd.
Phase 1 Unknown
Clinical Trials
271 trialsNCT04739670 2024-03-01
BELLA
Peter MacCallum Cancer Centre, Australia
Phase 2 Unknown
NCT03643549 2024-02-29
BORTEM-17
Haukeland University Hospital
Phase 1/2 Unknown
NCT05861947 2024-01-31
JIVAN
Aurigene Discovery Technologies Limited
Phase 1 Unknown
NCT05910970 2024-01-23
PREVENT-2
Guangxi Medical University
Phase 3 Unknown
NCT05415475 2024-01-05
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors
Chongqing Precision Biotech Co., Ltd
Phase 1 Unknown
NCT04266327 2023-12-27
RISI in the Treatment of Recurrent Metastatic SCC of Thoracic Inlet Lymph Nodes
Peking University Third Hospital
Phase NA Unknown
NCT03236129 2023-12-18
DLI-Boost
Assistance Publique - Hôpitaux de Paris
Phase 3 Unknown
NCT04089215 2023-11-24
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 2 Unknown
NCT06103617 2023-11-18
Safety and Superiority of Penicillamine in Radiosensitization of Recurrent Head and Neck Cancer
Nanfang Hospital, Southern Medical University
Phase 2 Unknown
NCT02624128 2023-11-13
V-CHANCE
National Cancer Institute, Naples
Phase 2 Unknown
NCT06074107 2023-10-11
Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects
BeBetter Med Inc
Phase 2 Unknown
NCT05626829 2023-10-06
Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma
Nanfang Hospital, Southern Medical University
Phase 2 Unknown
NCT04825496 2023-09-21
Clinical Study of ssCART-19 Cells in Patients With CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1 Unknown
NCT04969107 2023-08-08
Abdominal or Transanal TME for Rectal Cancer Therapy
Cantonal Hospital of St. Gallen
Phase NA Unknown
NCT03505554 2023-08-07
CRU3
University of Milano Bicocca
Phase 2 Unknown
NCT05951855 2023-07-19
Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT02825836 2023-07-13
Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects
Telios Pharma, Inc.
Phase 1/2 Unknown
NCT05940051 2023-07-11
Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT05397184 2023-07-05
TvT CAR7
Great Ormond Street Hospital for Children NHS Foundation Trust
Phase 1 Unknown
NCT04671459 2023-06-28
TaRRGET
Prof. Franciszek Lukaszczyk Memorial Oncology Center
Phase 2 Unknown
NCT05576532 2023-06-28
Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Unknown
NCT05920876 2023-06-27
A Study of QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma
Qilu Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT05250791 2023-06-09
FLICOR
Imperial College London
Phase NA Unknown
NCT05895370 2023-06-08
GI-HPVT-01
BGI, China
Phase 1 Unknown
NCT04761146 2023-05-25
DaRT-V
Cambridge University Hospitals NHS Foundation Trust
Phase NA Unknown
NCT05876052 2023-05-25
POTERE
University of Bologna
Phase NA Unknown
NCT05487651 2023-05-18
ANCHOR2
Athenex, Inc.
Phase 1 Unknown
NCT05105867 2023-05-10
CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Phase EARLY_PHASE1 Unknown
NCT05816746 2023-05-09
Decitabine and Anti-PD-1 in R/R DLBCL
Chinese PLA General Hospital
Phase 2 Unknown
NCT03510767 2023-04-14
A Study of TQ-B3525 on Tolerance and Pharmacokinetics
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT01675219 2023-04-13
Fluorescence Cystoscopy and Optimized MMC in Recurrent Bladder Cancer (FinnBladder 9)
Turku University Hospital
Phase 3 Unknown
NCT05797948 2023-04-04
GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
The First Affiliated Hospital of Soochow University
Phase NA Unknown
NCT05084586 2023-03-28
Comparison of the Efficacy and Safety of Continuous and Single-Dose Intravesical Epirubicin Instillation
Ankara Training and Research Hospital
Phase NA Unknown
NCT04749355 2023-03-09
Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS
BioSight Ltd.
Phase 2 Unknown
NCT02761070 2023-03-08
RE-GEND
Kyorin University
Phase 3 Unknown
NCT04933825 2023-02-17
A Study of ET-02 in Patients With Relapsed or Refractory B-cell Malignancy(NHL/ALL)
EdiGene (GuangZhou) Inc.
Phase NA Unknown
NCT05727683 2023-02-14
CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 1 Unknown
NCT04113226 2023-02-08
Relyage
Centre Hospitalier Universitaire, Amiens
Phase 2 Unknown
NCT04706936 2023-02-06
Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Unknown
NCT04887025 2023-02-06
Exploratory Study of a Novel Oncolytic Vaccinia Virus RGV004 in the Treatment of Refractory/Relapsed B-cell Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Unknown
NCT05585996 2023-02-06
Exploratory Clinical Study of CD19-targeted CAR-T and CAR-DC in the Treatment of Relapsed and Refractory B-cell Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Unknown
NCT05339607 2023-02-02
ERASE-pilot
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase NA Unknown
NCT05704231 2023-01-30
The Effect of Telephone-Assisted Smoking Cessation Program in Patients Diagnosed With Non-Muscle Invasive Bladder Cancer
Bakirkoy Dr. Sadi Konuk Research and Training Hospital
Phase NA Unknown
NCT05007418 2023-01-17
Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma
Sorrento Therapeutics, Inc.
Phase 1 Unknown
NCT05645601 2022-12-09
CAR-NK Targeted CD19 for r/r B-cell Malignancies
Affiliated Hospital to Academy of Military Medical Sciences
Phase 1 Unknown
NCT03825367 2022-10-12
Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1/2 Unknown
NCT05559177 2022-09-29
An Open, Dose-escalation Clinical Study of Chimeric Exosomal Tumor Vaccines for Recurrent or Metastatic Bladder Cancer
Shanghai Pudong Hospital
Phase EARLY_PHASE1 Unknown
NCT05557903 2022-09-28
Phase â… Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL
Lanzhou Institute of Biological Products Co., Ltd
Phase 1 Unknown
NCT05150457 2022-09-27
Safety and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors
Binacea Pharma, Inc.
Phase 1 Unknown